MDMA and MDMA-Assisted Therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing clinical trials, pharmacology, and policy considerations without systematic review methodology.
PubMed 39741438 · doi:10.1176/appi.ajp.20230681
What was done
This narrative review summarizes clinical trial evidence, putative neurobiological mechanisms, and regulatory/public health considerations for MDMA-assisted therapy (MDMA-AT) in posttraumatic stress disorder (PTSD). It contrasts findings from controlled clinical trials using pharmaceutical-grade MDMA against observational data on recreational use.
What was found
Following a treatment course of three MDMA sessions combined with psychotherapy, 67% to 71% of participants with PTSD no longer met diagnostic criteria, compared with 32% to 48% of participants receiving placebo-assisted therapy. The abstract notes that these therapeutic effects persisted at long-term follow-up, and that MDMA uniquely produces prosocial effects such as enhanced trust and self-compassion while preserving cognitive lucidity and ego functioning.
Why it matters
This review provides an overview of MDMA-AT following the FDA's 2024 decision to require an additional phase 3 trial prior to approval. It clarifies the distinction between controlled therapeutic protocols and recreational use.
Limits
The paper is a narrative review rather than a systematic review or meta-analysis, and trial selection criteria are not detailed. The abstract omits specific sample sizes, effect sizes, statistical confidence intervals, and adverse event frequencies across the cited studies. Inherent trial design challenges such as functional unblinding in psychedelic studies are not quantified in the abstract.
Cited by
- supports MDMA recently failed to receive FDA approval for the treatment of PTSD.